This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Messenger RNAs with multiple “tails” could lead to more effective therapeutics By Corie Lok March 22, 2024 Breadcrumb Home Messenger RNAs with multiple “tails” could lead to more effective therapeutics Scientists have engineered long lasting mRNAs that increased therapeutic proteinproduction in cells and animals.
A new study reveals that C1q can also enter neurons, where it influences proteinproduction, and can accumulate within neurons over time. They also suggest that C1q influences learning, memory, and flexibility in the adult brain, potentially by interacting with specific complexes within neurons that impact proteinproduction.
Now, researchers at MIT and the Broad Institute of MIT and Harvard have developed RIBOmap, a technique that lets them pinpoint and visualize the precise locations of thousands of proteins being produced within an intact tissue and even individual cells. By Sarah C.P. Williams June 29, 2023 Credit: Zeng H, Huang J, Ren J, et al.
is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.
As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I wanted to use molecular biology to create drugs.
Credit: Universität Würzburg Archives His key insight hinged upon the fact that living cells are essentially bags of liquid filled with enzymes, or proteins that speed up chemical reactions. Water accounts for 70 percent of a bacterium by mass; the other 30 percent includes everything else: proteins, RNA, DNA, lipids, and so on.
The most compelling evidence for the origin lies in the RNA genome sequence similarities between RaTG13 and SARS-CoV-2 – specifically, a part that encodes the “furin binding site” of the spike protein with which the virus adheres to host cells. Coincidence? I’ve never thought so. b) in an abandoned mine shaft?
Basic Science A trailing ribosome speeds up RNA polymerase at the expense of transcript fidelity via force and allostery. Ribozyme-mediated RNA synthesis and replication in a model Hadean microenvironment. Peroxisomal metabolic coupling improves fatty alcohol production from sole methanol in yeast. Szymczak P. Krypotou E.
Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase. “The virus hijacks this protein and makes it do something different than its normal job in cells.
The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.
The researchers first compared the editing efficiency of different versions of IscB when coupled with 'ωRNA,' which guides the enzyme to the right spot on the DNA. A particular variant, named IscB*-ωRNA*, had the highest editing efficiency across multiple different sites in the genome. Read more in Nature Methods.
Drug Discovery Today: Disease Models (2008). Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Link Artificial Gene Regulatory Networks—A Review , by Cussat-Blanc S. & Ueda T.
Drug Discovery Today: Disease Models (2008). Link A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , by Jinek M. Link The PURE system for the cell-free synthesis of membrane proteins , by Kuruma Y. & Link Artificial Gene Regulatory Networks—A Review , by Cussat-Blanc S. & Ueda T.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content